Male; 68 years old. Reason: R/O HCC History: Hx TACE/RFA, HCV, cirrhosis LIVER, BILIARY TRACT: Nodular liver contour is compatible with cirrhosis.Wedge shaped defect in segment 2/3 is compatible with the patient's chemoembolization/ablation defect. There is a lesion within the ablation bed that demonstrates intrinsic high T1 signal and measures up to 1.1 x 1.0 cm, unchanged (series 901/241). Again, there is questionable arterial enhancement and washout (only on subtraction images), and as a result, the lesion remains indeterminate and continued imaging follow-up is recommended.An additional nodular lesion near the ablation zone in segment 4 also demonstrates high T1 signal and mild enhancement without definite washout. This lesion measures 1.1 x 1.0 cm, unchanged (series 903/248).Near the dome of the liver, there is a T1 hyperintense, T2 hypointense lesion that does not demonstrate enhancement and measures 1.1 x 0.9 cm, unchanged and again most compatible with a dysplastic nodule (series 901/356). An additional punctate T1 hyperintense lesion in the right hepatic lobe is too small to accurately characterize and may be an additional dysplastic nodule (series 901/111).No biliary ductal dilatation. Patent hepatic vasculature. SPLEEN: Mild splenomegaly.PANCREAS: No significant abnormality noted.ADRENAL GLANDS: No significant abnormality noted.KIDNEYS, URETERS: No significant abnormality noted.RETROPERITONEUM, LYMPH NODES: No significant abnormality noted.BOWEL, MESENTERY: No significant abnormality noted.BONES, SOFT TISSUES: No significant abnormality noted.OTHER: No significant abnormality noted.
No significant interval change in post therapy changes of the liver. Segment 2/3 ablation bed lesion is again indeterminate, but stable, and continued imaging follow-up is recommended. Close attention on follow-up for additional T1 hyperintense lesions described above is also recommended.